New vaccine trial aims to protect transplant patients from bird flu pandemic
NCT ID NCT07240558
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a two-dose pandemic H5N1 (bird flu) vaccine in 120 organ transplant recipients to see if it is safe and produces a strong immune response. Transplant patients are especially vulnerable to severe flu, and there is no data yet on how well this vaccine works in them. Participants must be at least 18 years old, more than 3 months post-transplant, and have stable kidney function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AVIAN INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Health Network
RECRUITINGToronto, Ontario, M5G2N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI toolkit aims to speed up epidemic response for diseases like COVID-19 and mpox
- Hospital push could shield seniors from preventable diseases
- Meningitis b vaccine shows promise in children
- Teens' sleep habits may boost vaccine power
- Simple exercise test may reveal hidden risks in flu patients
- Nutrient sachets may boost vaccination rates in rural africa